BusinessMinerva Neurosciences Announces Recent Exercise of Warrants by Institutional Stockholders and Open Market Purchase of Common Stock by Chairman of Its Board of DirectorsBy Nasdaq OMXMar 21, 2017, 8:10 PM UTC
BusinessMinerva Neurosciences Reports Fiscal 2016 Fourth Quarter and Year End Financial Results and Business UpdatesBy Nasdaq OMXMar 13, 2017, 11:30 AM UTC
BusinessMinerva Neurosciences to Report Fiscal 2016 Fourth Quarter and Year End Financial Results and Business Updates on March 13, 2017By Nasdaq OMXMar 6, 2017, 1:30 PM UTC
BusinessMinerva Neurosciences to Present at Cowen and Company 37th Annual Health Care Conference on March 7, 2017By Nasdaq OMXFeb 28, 2017, 1:30 PM UTC
BusinessMinerva Neurosciences to Host R&D Day Focused on Unmet Needs and Emerging Treatment Strategies in SchizophreniaBy Nasdaq OMXFeb 21, 2017, 1:30 PM UTC
BusinessAdditional Data Analyses From Phase IIb Trial of MIN-101 in Schizophrenia Underscore Benefit in Multiple Measurements of Cognitive FunctionBy Nasdaq OMXJan 20, 2017, 1:30 PM UTC
BusinessMinerva Neurosciences Names Michael Davidson, M.D. as Chief Medical OfficerBy Nasdaq OMXDec 20, 2016, 1:30 PM UTC
BusinessMinerva Neurosciences’ Clinical Data Featured at The American College of Neuropsychopharmacology Annual MeetingBy Nasdaq OMXDec 5, 2016, 1:00 PM UTC
